Clinical Trial

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-03-14; most recent amendment 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2022-04-19
Trial Details
NCT Number NCT05279300
Lead Sponsor CStone Pharmaceuticals
Conditions Advanced Solid Tumor, Advanced Lymphoma
Enrollment 480 participants
Start Date 2022-03-28
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-11